S&P Futures
3,989.00 +18.50 (+0.47%) Dow Futures
32,403.00 +145.00 (+0.45%) Nasdaq Futures
12,765.00 +58.00 (+0.46%) Russell 2000 Futures
1,755.30 +14.30 (+0.82%) Crude Oil
70.18 -0.72 (-1.02%) Gold
1,977.10 +27.50 (+1.41%)
Astria Therapeutics, Inc. (ATXS)
Chart Events
Performance Outlook
| Previous Close | 11.22 |
| Open | 11.13 |
| Bid | 11.49 x 900 |
| Ask | 11.61 x 1100 |
| Day's Range | 10.61 - 11.64 |
| 52 Week Range | 2.36 - 16.28 |
| Volume | |
| Avg. Volume | 237,513 |
| Market Cap | 320.115M |
| Beta (5Y Monthly) | 0.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -33.68 |
| Earnings Date | May 10, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.67 |
- Business Wire
Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
BOSTON, March 22, 2023--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.
- Business Wire
Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd
BOSTON, March 08, 2023--Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter/full year 2022 financial results before the Nasdaq Global Market open on Wednesday, March 22, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an up
- Business Wire
Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference
BOSTON, March 06, 2023--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming virtual Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13th at 1:20pm ET.
